BC-3人淋巴瘤细胞

取材于85岁男性患者。经无支原体鉴定入库。

动物种别/Organism    人

组织来源 Tissue and Cell Type   胸腔积液

形态/Morphology 淋巴母细胞样，悬浮生长

培养基和添加剂/Complete Growth Medium and Culture Conditions：

80%1640(MD0200)+20%胎牛血清(SD0200)+L-glutamine(SD0007)+SP（SD0008）+G/A (SD0038)

完全培养基：1640完全培养基（货号：MD0219）

气相：空气，95%；二氧化碳，5%。 温度：37摄氏度。

（备注：保持细胞密度在5x105~ 2x106 /ml 活细胞之间，不可过密或过稀）

冻存条件：基础培养基+5%DMSO+20%FBS(SD0200)

完全冻存液：免程序降温细胞冻存液（低血清）(SD0001) 

注意事项：此产品仅供科研使用

PubMed=8839859; DOI=10.1182/blood.V88.7.2648.bloodjournal8872648

Arvanitakis L., Mesri E.A., Nador R.G., Said J.W., Asch A.S., Knowles D.M., Cesarman E.

Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus.

Blood 88:2648-2654(1996)

DOI=10.1016/B978-0-12-221970-2.50457-5

Drexler H.G.

The leukemia-lymphoma cell line factsbook.

(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=15613351; DOI=10.1128/JVI.79.2.1244-1251.2005

Fan W., Bubman D., Chadburn A., Harrington W.J. Jr., Cesarman E., Knowles D.M.

Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association.

J. Virol. 79:1244-1251(2005)

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

PubMed=21685375; DOI=10.1182/blood-2010-12-323659

Roy D., Sin S.-H., Damania B., Dittmer D.P.

Tumor suppressor genes FHIT and WWOX are deleted in primary effusion lymphoma (PEL) cell lines.

Blood 118:E32-E39(2011)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747

Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Cancer Res. 79:1263-1273(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x

Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.

The LL-100 panel: 100 cell lines for blood cancer studies.